

Mayo Clinic Updates in CAR-T Cell Therapy 2021 – LIVESTREAM

August 26 – 27, 2021

Central Time Zone

Thursday, August 26, 2021

General Session

9:50am	Opening Remarks / Welcome <i>Saad J. Kenderian, M.B., Ch.B. and Yi Lin, M.D., Ph.D.</i>
10:00am	B-Cell Acute Lymphoblastic Leukemia: CD19 Targeting – Current status and limitations and Beyond CD19 – Future Directions <i>Nirali N. Shah, M.D., M.H.Sc., NIH</i> <i>Haneen Shalabi, D.O., NIH</i>
10:45 am	Non-Hodgkin's Lymphoma – Clinical Trials/Research Focus <i>Tanya Siddiqi, M.D., City of Hope (Clinical Trials/Research)</i> Real world experience with CAR T-cell therapy in NHL <i>Sattva S. Neelapu, M.D., MD Anderson Cancer Center (Real World Practice)</i>
11:30am	Multiple Myeloma <i>Nina Shah, M.D., University of California San Francisco</i>
12:00pm	Break
12:30pm	Toxicity – CRS/ICANS <i>Jae Park, M.D., Memorial Sloan Kettering Cancer Center</i>
1:00pm	Toxicities and Immune Activation Post CART Cell Therapy: Lesson Learned <i>Saad J. Kenderian, M.B., Ch.B.</i>
1:45pm	Challenges of CAR-T and COVID-19 <i>Hemant S. Murthy, M.D.</i>
2:15pm	Wrap-Up/Closing Remarks – reminders about the next day's session
2:30pm	Adjourn

Friday, August 27, 2021

Concurrent Sessions

#1 – Clinical Research

9:50am	Day 2 Opening Remarks / Welcome <i>Saad J. Kenderian, M.B., Ch.B. and Yi Lin, M.D., Ph.D.</i>
10:00am	T-cell Lymphoma: CD5, CD7 <i>LaQuisa Hill, MD, M.D., Baylor College of Medicine</i>
10:30am	CD30 CART <i>Barbara Savoldo, M.D., Ph.D., UNC School of Medicine</i>
11:00am	GBM CART <i>Christine Brown, Ph.D., City of Hope</i>
11:30am	Other CART Innovations <i>Hong Qin, M.D., Ph.D.</i>
12:00pm	Break
12:30pm	iPSC and other Off-the-Shelf IEC Platforms <i>Januario E. Castro, M.D., Mayo Clinic Arizona</i>
1:00pm	CAR-NK <i>May Daher</i>
1:30pm	UCART <i>Reuben Benjamin, UCL</i>
2:00 pm	Break (as we transition to general session)
#2 – Immune Effector Cell Program Administration – Group Discussions	
9:50am	Day 2 Opening Remarks / Welcome <i>Eapen K. Jacob, M.D. and Matthew A. Hathcock</i>
10:00am	CIBMTR and Regulatory Reporting

	<i>Matthew A. Hathcock</i>
10:30am	FACT IEC Program New Standards and Virtual Inspections <i>Eapen K. Jacob, M.D.,</i> <i>Panelists: Jill Petersen, MSN, RN, Monica Shaw</i>
11:00am	Working with a Commercial Manufacturer <i>Michael C. Deeds and Alexis A. Jackson, M.S.</i> <i>Panelists: Indresh Kaur, MDACC, Peter Ferreira-Gandolfo, OHSU, Sarah Malakian, MT(ASCP), MCA</i>
11:30am	Industry Manufacturer and FDA Approved Therapies <i>Gina M. Lange, R.N.</i> <i>Panelist Misha Hawkins, MDACC</i>
12:00pm	Break
12:30pm	Logistics of Clinical Trials <i>Jared L. Bruggeman, CCRP</i> <i>Panelists: Jenai Wilmoth, UCSF; Sherry Adkins, MDACC</i>
1:15pm	Coordinating Institutional Resources for Commercial and In-house Manufactured Products <i>Hollie L. Benson and Michael P. Gustafson, Ph.D.</i> <i>Panelists: Indresh Kaur, MDACC; Peter Ferreira-Gandolfo, OHSU, Sarah Malakian, MT(ASCP), MCA</i>
2:00pm	Break (as we transition to general session)
#3 – Immune Effector Cell Program Provider Team – Group Discussions	
9:50am	Day 2 Opening Remarks / Welcome <i>Urshila Durani, M.D., M.P.H. and Megan T. Spsychalla, P.A.-C.</i>
10:00am	Case Studies: <i>Allison (Alli) L. McClanahan, APRN, C.N.P.</i> <i>Panelists: Samantha Shenoy, UCSF, Bindu Kuriacose, MDACC</i>
10:45am	Outpatient Practice <i>Megan T. Spsychalla, P.A.-C.</i> <i>Panelists: Samantha Shenoy, UCSF, Bindu Kuriacose, MDACC</i>
11:15am	Supportive Management <i>Adrienne N. Nedved, Pharm.D., R.Ph. or Jason N. Barreto, Pharm.D.</i> <i>Panelist: Tina Nguyen, COH</i>
11:45am	Complications <i>Adrienne N. Nedved, Pharm.D., R.Ph. or Jason N. Barreto, Pharm.D.</i> <i>Panelist: Tina Nguyen, COH</i>
12:15pm	Break
12:45pm	Long-term Follow Up <i>Urshila Durani, M.D., M.P.H.</i>
1:15pm	Grant and Supportive Resources <i>Emily R. Blackmer, M.S.W.</i>
2:00pm	Break (transition to general session)
2:15pm	Breakout Session Recap (15 min. each) • #1 – MD, Ph. D, Research Focused ○ <i>Saad J. Kenderian, M.B., Ch.B. and Yi Lin, M.D., Ph.D.</i> • #2 – Immune Effector Cell Program Administration ○ <i>Eapen K. Jacob, M.D. and Matthew A. Hathcock</i> • #3 – Immune Effector Cell Program Provider Team ○ <i>Urshila Durani, M.D., M.P.H. and Megan T. Spsychalla, P.A.-C.</i>
3:00pm	Course Wrap-Up
3:15pm	Adjourn



Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 8.0 knowledge-based contact hours. Participants should only claim credit commensurate with the extent of their participation in the activity.

Universal Activity Number (UAN): JA0000238-0000-21-090-L01-P